Patel Purva, Gaddis Monica, Xu Xuan, Riviere Jim E, Kawakami Jessica, Meyer Emma, Jaberi-Douraki Majid, Wyckoff Gerald J
Division of Pharmacology and Pharmaceutical Sciences, UMKC School of Pharmacy, UMKC, Kansas City, MO, USA.
Division of Biomedical and Health Informatics, UMKC School of Medicine, UMKC, Kansas City, MO, USA.
Heliyon. 2023 Mar;9(3):e13763. doi: 10.1016/j.heliyon.2023.e13763. Epub 2023 Feb 24.
Initial studies in COVID-19 patients reported lower mortality rates associated with the use of the drug heparin, a widely used anticoagulant. The objective of this analysis was to determine whether there are adverse events associated with the administration of anticoagulants, and specifically how this might apply in patients known to have COVID-19. Data for this study were obtained from the Food and Drug Administration's Adverse Event Reporting System (FAERS) public database and from the NIH's clinical trials website. Proportional Reporting Ratios (PRR) with lower 95% confidence intervals (lower CI) and empirical Bayes geometric mean (EBGM) scores with lower 95% confidence limits were calculated for data from the FAERS database where the adverse events studied mimicked COVID-19 symptoms.
对新冠肺炎患者的初步研究报告称，使用肝素（一种广泛使用的抗凝剂）可降低死亡率。本分析的目的是确定使用抗凝剂是否存在不良事件，特别是在已知患有新冠肺炎的患者中情况如何。本研究的数据来自美国食品药品监督管理局不良事件报告系统（FAERS）公共数据库以及美国国立卫生研究院的临床试验网站。对于FAERS数据库中不良事件类似新冠肺炎症状的数据，计算了95%置信区间下限较低的比例报告比（PRR）和95%置信下限较低的经验贝叶斯几何均值（EBGM）得分。
